TORONTO & SAN FRANCISCO, February 14, 2024 Treadwell Therapeutics, a privately held clinical-stage biotechnology company pioneering and advancing novel first-in-class medicines for unmet needs in cancer, today announced the formation of a Scientific Advisory Board comprised of prominent oncology leaders and drug developers. The SAB will work closely with Treadwell to advance the company’s pipeline of small molecules, biologics and cell therapies.
Adding deep preclinical and clinical immuno-oncology expertise to expand InteRNA's preclinical pipeline and accelerate clinical-stage lead candidate INT-1B3 InteRNA Technologies, a clinical-stage